Core Insights - BW Energy Limited held its Annual General Meeting in 2025, discussing key operational and strategic updates [1] Company Overview - BW Energy is a growth-oriented exploration and production (E&P) company focusing on proven offshore oil and gas reservoirs through low-risk phased developments [2] - The company has access to existing production facilities, which allows for reduced time to first oil and cash flow with lower investments compared to traditional offshore developments [2] Asset Portfolio - BW Energy holds a 73.5% interest in the producing Dussafu Marine licence offshore Gabon, a 100% interest in the Golfinho and Camarupim fields, a 76.5% interest in the BM-ES-23 block, a 95% interest in the Maromba field in Brazil, and a 95% interest in the Kudu field in Namibia, all operated by the company [2] - Additionally, BW Energy owns approximately 6.6% of the common shares in Reconnaissance Energy Africa Ltd. and a 20% non-operating interest in the onshore Petroleum Exploration License 73 (PEL 73) in Namibia [2] Reserves and Resources - As of the start of 2025, BW Energy reported total net 2P+2C reserves and resources of 599 million barrels of oil equivalent [2]

Elis Capital Markets Day 2025 - Uniquely positioned for profitable and sustainable growth A financial strategy focused on enhancing shareholder returns London, 27 May 2025 - Elis, the leading multi-service provider of circular rental solutions for textiles, hygiene and wellness products, is today hosting its 2025 Capital Markets Day in London. During the event, CEO Xavier Martiré and members of the senior leadership team will present the Group’s strategic priorities and medium-term financial outlook. After ...

Quadient (Euronext Paris: QDT), a global automation platform powering secure and sustainable business connections, announces that more than 300 higher education institutions in the U.S. are now relying on Parcel Pending by Quadient Lockers for streamlined package pickup and drop-off, bookstore merchandise, class and IT equipment exchange points, and addressing the challenge of student food insecurity. Higher education institutions, from large public systems to private colleges, depend on Parcel Pending by Q ...

VANCOUVER, British Columbia, May 27, 2025 (GLOBE NEWSWIRE) -- Cornish Metals Inc. (AIM/TSX-V: CUSN) (“Cornish Metals” or the “Company”), a mineral exploration and development company focused on advancing its 100% owned and permitted South Crofty tin project in Cornwall, United Kingdom, announces that on 23 May 2025, the Company granted conditional performance share awards (“Performance Awards”) under the new Cornish Metals Long Term Incentive Plan (“LTIP”) which was approved by shareholders on 18 March 2025 ...

Please see below information about transactions made under the second tranche of the 2025 share buy-back programme for Equinor ASA (OSE:EQNR, NYSE:EQNR, CEUX:EQNRO, TQEX:EQNRO). Date on which the buy-back tranche was announced: 30 April 2025. The duration of the buy-back tranche: 16 May to no later than 21 July 2025. Further information on the tranche can be found in the stock market announcement on its commencement dated 30 April 2025, available here: https://newsweb.oslobors.no/message/644796 From 20 May ...

Core Viewpoint - Trifork has appointed Charmaine Carmichael as the Group COO and UK Director, aiming to enhance its global growth strategy and product-centric transition [1][6][7]. Group 1: Appointment Details - Charmaine Carmichael will join Trifork on 1 July 2025 [9]. - The new role of Group COO and UK Director is created to strengthen Trifork's operational leadership [1][6]. Group 2: Charmaine Carmichael's Background - Charmaine brings over 25 years of executive technology leadership experience, having worked with Fortune 500 companies and high-growth start-ups [2]. - Prior to Trifork, she was Managing Director and Partner at McKinsey & Company, focusing on digital business initiatives across various sectors [3]. - She also held leadership roles at BCG Digital Ventures and Nokia, and was involved in significant operations at Research in Motion (BlackBerry) [4]. Group 3: Strategic Goals - As Group COO, Charmaine will shape and execute Trifork's global growth strategy, focusing on strategic partnerships and a product-centric future [6]. - Her leadership is expected to drive the organisational transition and enhance the unified local go-to-market strategy in the UK [6][8]. Group 4: Company Overview - Trifork is a global technology company with 1,215 professionals across 71 business units in 16 countries, specializing in advanced software solutions for various sectors [10]. - The company is listed on Nasdaq Copenhagen under the ticker TRIFOR and has a strong focus on innovation through its R&D arm, Trifork Labs [10].

Core Viewpoint - CROSSJECT is enhancing its manufacturing capabilities with the implementation of the ZENEO® Nest module, aimed at scaling up production in anticipation of the deployment of its product pipeline, particularly the ZEPIZURE® emergency injectable for epilepsy management [2][3]. Group 1: Manufacturing Innovations - The ZENEO® Nest is designed for automated, high-volume aseptic filling of proprietary glass drug containers, allowing for faster and more efficient production [3][4]. - This new module is compatible with various filling setups in the CDMO industry, enabling CROSSJECT to establish ready-to-use filling units with CDMO partners globally as demand increases [3][5]. Group 2: Implementation Timeline - The first ZENEO® Nest has been successfully tested with EUROFINS, and full implementation is expected by December 2025, followed by qualification and validation steps by Q1 2026 [4][9]. Group 3: Financial Aspects - The deployment of the ZENEO® Nest is partially financed through an equipment loan from LCL, reflecting CROSSJECT's strategy to diversify its financing sources [6][9]. Group 4: Company Overview - CROSSJECT is a specialty pharmaceuticals company focused on developing emergency medications, with its ZENEO® platform facilitating easy delivery of drugs via intramuscular injection [7][8]. - The company is in advanced regulatory development for ZEPIZURE®, supported by a $60 million contract with BARDA [7].

Core Points - Vallourec announces a share repurchase program to buy back approximately 1.2 million shares by June 20, 2025, aimed at managing future equity dilution and supporting employee long-term incentive plans [1][2] Company Overview - Vallourec is a global leader in premium seamless tubular solutions, serving energy markets and demanding industrial applications, including oil & gas wells, power plants, and high-performance mechanical equipment [3] - The company employs nearly 13,000 people across more than 20 countries, focusing on delivering innovative and competitive tubular solutions [3] Stock Information - Vallourec is listed on Euronext Paris and is part of several indices, including CAC Mid 60, SBF 120, and Next 150 [4] - The company has a sponsored Level 1 American Depositary Receipt (ADR) program in the United States, with a parity set at 5:1 between ADR and ordinary shares [4]

Core Points - Nicox SA has announced that its exclusive Japanese partner Kowa has received approval to initiate Phase 3 clinical trials for NCX 470, which will trigger a €1 million milestone payment to Nicox [1][5] - A total of €3 million in milestone payments from Kowa is expected in 2025, which will extend Nicox's cash runway until at least the end of 2025 [2][3][5] - NCX 470 is a novel NO-donating bimatoprost eye drop aimed at treating ocular hypertension and is currently in Phase 3 clinical development [8][9] Company Developments - The initiation of Phase 3 clinical trials for NCX 470 in Japan is expected in the second half of 2025, with a second milestone payment of €2 million upon initiation [1][6] - Nicox licensed the rights to develop and commercialize NCX 470 in Japan to Kowa in February 2024, with potential additional milestone payments of up to €7 million and tiered royalties from 7% to 12% on net sales [7][9] - The ongoing Denali Phase 3 clinical trial is evaluating NCX 470 in patients with open-angle glaucoma or ocular hypertension, with topline results expected in Q3 2025 [6][8] Financial Outlook - Based on current cash position and anticipated milestone payments, Nicox estimates it is financed until the end of 2025 [3] - The company generates revenue from other products, including ZERVIATE® and VYZULTA®, which are licensed in multiple geographies [9]

Group 1 - Aalberts has repurchased 39,141 shares from May 19, 2025, to May 23, 2025, for a total of EUR 1,152,277.52, averaging EUR 29.44 per share [1] - A cumulative total of 1,835,369 shares has been repurchased under the buyback program for EUR 54,754,770 as of May 23, 2025 [2] - The share buyback program is part of a total allocation of EUR 75 million announced on February 27, 2025, and is set to conclude by October 24, 2025 [1][2] Group 2 - The buyback will be executed within the authority granted by the Annual General Meeting on May 23, 2024, and will comply with Market Abuse Regulation 596/2014 [3] - An intermediary has been engaged to conduct the share repurchases in the open market, independent of Aalberts [2] - The shares repurchased are intended to be cancelled following the buyback [1]